Agile Therapeutics, Inc. Honored as the 2011 Life Sciences Company of the Year by the New Jersey Technology Council

PRINCETON, NJ--(Marketwire - November 18, 2011) -

Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women’s contraceptive products, yesterday was honored with the 2011 Life Science Company of the Year Award by the New Jersey Technology Council (NJTC), a not-for-profit organization supporting growth in New Jersey’s various technology sectors, including health sciences.

“Agile Therapeutics was selected as the 2011 Life Sciences Company of the Year for their impact on the life science industry, rate of growth, outstanding contributions to industry and overall success,” said Maxine Ballen, founder and president, New Jersey Technology Council. “We are excited with the work Agile is doing to provide women with more convenient contraceptive options.”

“The New Jersey Technology Council has been a great support to Agile throughout the years. We are honored to receive the award for the Life Sciences Company of the Year,” said Al Altomari, president and CEO of Agile Therapeutics Inc. “We look forward to continuing our partnership with NJTC as we strive to close out our clinical trials for AG200-15 and file our NDA in early 2012.”

Agile Therapeutics received the award during the annual black-tie gala held at The Addison Park in Aberdeen, NJ. The NJTC Gala Awards is held annually to publicly recognize and celebrate some of New Jersey’s upcoming and most successful organizations. The awards gala highlights the Company of the Year winners in the fields of software, life science, electronics, communications, energy and nanotechnology as well as several individual awards.

About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women’s Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company’s lead product, AG200-15, is a once-weekly contraceptive patch currently in Phase III clinical trials. In addition, Agile is also developing a low-dose, progestin-only contraceptive patch, AG900. Both AG200-15 and AG900 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.

About the New Jersey Technology Council
The New Jersey Technology Council provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC’s almost 1,000 member companies work together to support their own enterprises while advancing New Jersey’s status as a leading technology center in the United States.